6th Orphan Drugs and Rare Diseases Europe 2017

SMi's 6th annual Orphan Drugs and Rare Diseases event will be taking place in Europe's largest pharmaceutical market, Berlin on 15th - 16th May 2017.

Rare diseases have long been under researched, with many unaware that such conditions even existed. However recent advancements within the orphan drugs landscape has resulted in a significant growth, with the market expected to reach a record breaking $191 billion by 2019. Conversely, there cannot be success without challenges.

With Germany currently possessing one of the toughest pricing mechanisms and policies in Europe, this two day conference will endeavor to establish an interactive platform exploring how payers, pharma, biotech and patient organisations are preparing to participate and leverage the rapidly growing orphan drugs and rare diseases market.

FEATURED SPEAKERS:
•Massimo Bertelli, Country Manager, Aegerion Pharmaceuticals
•Alastair Kent, Market Research Manager, Institute of Pharmaceutical Research & Technology
•Richard Porter, Chief Operating Officer, Therachon AG
•Peter Ramge, Senior Global Product Manager, Novo Nordisk
•Tony Zbeidy, General Manager Middle East & North Africa, Orphan Europe
•Jama Nateqi, Co-Founder, SYMPTOMA
•Cécile De Coster, Associate Directory, Regulatory Affairs, Alexion Pharma GmbH
• Carol McCudden, Patient Ambassador, ATAXIA UK

CONFERENCE HIGHLIGHTS:
•Exchange knowledge and best practices on all relevant issues related to the rare disease environment
•Learn strategies on defending the pricing of orphan products and how to establish a foundation for reimbursement
•Hear Alexion discuss criteria, comparison and case studies for US and EU regulatory landscapes
•Circulate the most relevant findings within the rare disease environment to all relevant stakeholders
•Listen to global case studies from Aegerion and Orphan Europe
•Discover a new business model for developing rare diseases treatments

Register at www.orphandrugs-event.com/evvnt

On Monday May 15, 2017